PL3054959T3 - Sposoby leczenia złośliwych nowotworów zwłóknieniowych - Google Patents

Sposoby leczenia złośliwych nowotworów zwłóknieniowych

Info

Publication number
PL3054959T3
PL3054959T3 PL14851638T PL14851638T PL3054959T3 PL 3054959 T3 PL3054959 T3 PL 3054959T3 PL 14851638 T PL14851638 T PL 14851638T PL 14851638 T PL14851638 T PL 14851638T PL 3054959 T3 PL3054959 T3 PL 3054959T3
Authority
PL
Poland
Prior art keywords
methods
treating fibrotic
fibrotic cancers
cancers
treating
Prior art date
Application number
PL14851638T
Other languages
English (en)
Inventor
Suzanne Bruhn
Elizabeth TREHU
Mark LUPHER
Original Assignee
Promedior Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc. filed Critical Promedior Inc.
Publication of PL3054959T3 publication Critical patent/PL3054959T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL14851638T 2013-10-08 2014-10-08 Sposoby leczenia złośliwych nowotworów zwłóknieniowych PL3054959T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US201462004828P 2014-05-29 2014-05-29
US201462004836P 2014-05-29 2014-05-29
EP14851638.8A EP3054959B1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers
PCT/US2014/059699 WO2015054390A1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers

Publications (1)

Publication Number Publication Date
PL3054959T3 true PL3054959T3 (pl) 2020-07-13

Family

ID=52813618

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14851638T PL3054959T3 (pl) 2013-10-08 2014-10-08 Sposoby leczenia złośliwych nowotworów zwłóknieniowych

Country Status (10)

Country Link
US (2) US11020451B2 (pl)
EP (2) EP3054959B1 (pl)
JP (2) JP6636914B2 (pl)
CN (2) CN114053395A (pl)
AU (2) AU2014331954B2 (pl)
CA (1) CA2926418A1 (pl)
ES (1) ES2784234T3 (pl)
PL (1) PL3054959T3 (pl)
RU (2) RU2020111934A (pl)
WO (1) WO2015054390A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3054959T3 (pl) 2013-10-08 2020-07-13 Promedior Inc. Sposoby leczenia złośliwych nowotworów zwłóknieniowych
JP2018512164A (ja) * 2015-04-15 2018-05-17 プロメディオール， インコーポレイテッド 骨髄増殖性障害を処置するための方法
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
WO2019152232A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CA3093749A1 (en) * 2018-03-28 2019-10-03 Blade Therapeutics, Inc. Method of treating fibrotic disease
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
WO2020219423A1 (en) * 2019-04-25 2020-10-29 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
EP4096653A4 (en) * 2020-01-28 2024-02-28 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
KR102725907B1 (ko) * 2021-11-25 2024-11-04 성균관대학교산학협력단 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법
KR20260016906A (ko) * 2023-03-17 2026-02-04 엠디엑스 메니지먼트 엘엘씨 요법의 유해효과를 개선하기 위한 조성물 및 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8012472B2 (en) * 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
PT2029173T (pt) * 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
PT2185581E (pt) * 2007-07-06 2015-12-09 Promedior Inc Processos e composições úteis no tratamento de mucosite
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
DK2405929T3 (en) 2009-03-11 2018-08-27 Promedior Inc SAP polypeptide for use in the treatment of autoimmune disorders and graft-versus-host disease
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) 2009-06-17 2015-11-24 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
PL3054959T3 (pl) 2013-10-08 2020-07-13 Promedior Inc. Sposoby leczenia złośliwych nowotworów zwłóknieniowych
JP2018512164A (ja) 2015-04-15 2018-05-17 プロメディオール， インコーポレイテッド 骨髄増殖性障害を処置するための方法

Also Published As

Publication number Publication date
EP3054959A1 (en) 2016-08-17
AU2014331954A1 (en) 2016-04-21
ES2784234T3 (es) 2020-09-23
JP2020059752A (ja) 2020-04-16
JP6636914B2 (ja) 2020-01-29
WO2015054390A1 (en) 2015-04-16
CA2926418A1 (en) 2015-04-16
JP2016539087A (ja) 2016-12-15
EP3718558A1 (en) 2020-10-07
RU2016117775A (ru) 2017-11-15
AU2020220139A1 (en) 2020-09-10
RU2020111934A (ru) 2020-04-29
JP7140739B2 (ja) 2022-09-21
US20160235812A1 (en) 2016-08-18
US11020451B2 (en) 2021-06-01
EP3054959A4 (en) 2017-04-26
AU2014331954B2 (en) 2020-05-21
CN105792831A (zh) 2016-07-20
US20210322515A1 (en) 2021-10-21
RU2016117775A3 (pl) 2018-07-27
EP3054959B1 (en) 2020-01-08
RU2718056C2 (ru) 2020-03-30
CN114053395A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
SG11201603050TA (en) Methods for treating cancers
PL3054959T3 (pl) Sposoby leczenia złośliwych nowotworów zwłóknieniowych
GB201323121D0 (en) Downhole Apparatus
GB201318983D0 (en) Radiotherapy apparatus
GB201323127D0 (en) Downhole apparatus
GB201406414D0 (en) Downhole Apparatus
SG11201610551TA (en) Combinations for treating cancers
SG11201508878WA (en) Methods of treating cancer
ZA201606954B (en) Mining apparatus
GB201306980D0 (en) Methods
PL3008082T3 (pl) Sposoby
PL3016682T3 (pl) Sposoby leczenia nowotworu
ZA201507762B (en) Methods of treating cancer
GB201312444D0 (en) Methods
GB201308516D0 (en) Methods
GB201401174D0 (en) pPost raising apparatus
GB201304801D0 (en) Downhole apparatus
GB201304234D0 (en) Methods
GB201415000D0 (en) Improved process
GB201402997D0 (en) Improved apparatus
GB2532369B (en) Mousehole apparatus
GB2500109B (en) Downhole Apparatus
GB2516659B (en) Structure formation apparatus
GB201322740D0 (en) Methods